Joshua Moriarty

Okogen, Inc. engages in the development of clinical theraphies to serve the needs of adult and children with ocular infections. Its lead candidate, OKG-0301, is a ribonuclease which targets degradation of specific tRNA and miRNA, which leads to inhibiting protein synthesis. It stops viral replication and shortens the duration of infection. The company was founded on July 1, 2016 and is headquartered in Encinitas, CA.

Okogen, Inc. engages in the development of clinical theraphies to serve the needs of adult and children with ocular infections. Its lead candidate, OKG-0301, is a ribonuclease which targets degradation of specific tRNA and miRNA, which leads to inhibiting protein synthesis. It stops viral replication and shortens the duration of infection. The company was founded on July 1, 2016 and is headquartered in Encinitas, CA.

Okogen, Inc. engages in the development of clinical theraphies to serve the needs of adult and children with ocular infections. Its lead candidate, OKG-0301, is a ribonuclease which targets degradation of specific tRNA and miRNA, which leads to inhibiting protein synthesis. It stops viral replication and shortens the duration of infection. The company was founded on July 1, 2016 and is headquartered in Encinitas, CA.